Welcome to our dedicated page for Cognex SEC filings (Ticker: CGNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cognex Corporation (CGNX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing a structured view of how this industrial machine vision issuer reports its financial and corporate information. Cognex is incorporated in Massachusetts and files under Commission File Number 001-34218, with its common stock listed on NASDAQ under the symbol CGNX.
Among the key documents available are Form 10-K annual reports and Form 10-Q quarterly reports, where Cognex discusses its machine vision business, risk factors, and financial statements. These filings are important for understanding trends in logistics and factory automation demand, as well as the company’s investment in AI-enabled vision products, as referenced in its public communications.
Investors will also find Form 8-K current reports that Cognex uses to announce material events. Recent 8-K filings include the release of quarterly financial results, dividend declarations, and an audit firm rotation in which the Audit Committee selected KPMG LLP as the independent registered public accounting firm for a future fiscal year, following Grant Thornton LLP. Such filings provide timely insight into corporate actions and governance decisions.
On this page, users can monitor real-time updates from EDGAR, including 8-Ks, 10-Qs, 10-Ks, and other forms that Cognex may file. Stock Titan’s tools offer AI-powered summaries that help explain the contents of lengthy filings, highlight key sections, and clarify technical language around accounting, risk disclosures, and strategic priorities. In addition, Form 4 insider transaction reports, when filed, can be accessed to review share transactions by Cognex officers, directors, or significant shareholders.
By using the CGNX filings page, investors and researchers can quickly move from raw SEC documents to clearer explanations of how Cognex presents its financial condition, machine vision strategy, and corporate developments in official filings.
COGNEX CORP director Sachin Lawande reported equity awards and an RSU conversion. On February 18, 2026, 8,324 restricted stock units were exercised or converted into 8,324 shares of common stock at a stated price of $0.00 per share, leaving 25,518 common shares held directly.
On February 17, 2026, Lawande received a grant of 4,817 restricted stock units, each representing a contingent right to one share of Cognex common stock. Footnotes state that one RSU grant vests 100% on the first anniversary of the February 18, 2025 grant date, and another vests 100% on the first anniversary of the February 17, 2026 grant date.
COGNEX CORP executive Carl Gerst reported multiple equity award transactions. On February 17, 2026, he received a grant of 24,854 non-qualified stock options and 24,085 restricted stock units (RSUs), each at a price of $0.00 per share.
The options vest in five approximately equal annual installments on the first through fifth anniversaries of the February 17, 2026 grant date. The RSUs granted on that date vest approximately 20%, 30%, and 50% on the first, second, and third anniversaries, respectively. Each RSU represents a contingent right to receive one share of Cognex common stock.
On February 18, 2026, 5,570 RSUs vested and were converted into 5,570 shares of common stock. Of these, 1,766 shares were withheld at $56.72 per share to satisfy tax withholding obligations, leaving 3,804 common shares directly held afterward.
Cognex Corp VP and principal accounting officer Laura Ann Macdonald reported multiple equity transactions. On February 17, 2026, she received a grant of 7,231 non-qualified stock options and 11,211 restricted stock units (RSUs), each RSU representing the contingent right to one common share. The options vest in five approximately equal annual installments beginning on the first anniversary of the grant date, while the RSUs vest 20%, 30%, and 50% on the first, second, and third anniversaries of the grant date.
On February 18, 2026, 2,422 RSUs vested and were converted into the same number of common shares. Of these, 711 shares, valued at $56.72 per share, were withheld to satisfy tax withholding obligations, leaving her with 3,923 directly held common shares and 9,685 RSUs. An additional 20 common shares are held indirectly by her child, for which she disclaims beneficial ownership except to the extent of her pecuniary interest.
Cognex Corporation executive Sheila Marie DiPalma, EVP of Employee Services, reported several equity compensation transactions. On February 17, 2026, she received a grant of 13,557 non-qualified stock options and 13,138 restricted stock units (RSUs), both at a price of $0.00. The options vest in five approximately equal annual installments starting one year after the grant date, while the RSUs vest 20%, 30%, and 50% on the first, second, and third anniversaries.
On February 18, 2026, 3,027 RSUs were exercised and converted into common stock at $0.00, increasing her directly held common shares, and 1,022 common shares at $56.72 were withheld to satisfy tax obligations related to the vesting. After these transactions, she held 8,587 shares of common stock directly and maintained derivative holdings including RSUs and stock options as reported.
COGNEX CORP director Robert Willett reported equity award activity tied to restricted stock units that vested on February 18, 2026. A total of 14,165 restricted stock units were converted into common shares at no cost and are held indirectly by the Willett Parkhill Investment Trust, where he is trustee and beneficiary and disclaims beneficial ownership beyond his economic interest.
To cover tax obligations on this vesting, the trust disposed of 6,849 common shares at $56.72 per share through share withholding rather than an open-market sale. The underlying RSU grant vests in tranches of approximately 20%, 30%, and 50% on the first, second, and third anniversaries of the February 18, 2025 grant date.
Cognex director Anthony Sun reported equity award activity and updated holdings. On February 18, 2026, 8,324 restricted stock units were exercised or converted at an exercise price of $0.00 per unit, resulting in 8,324 shares of common stock and bringing his directly held common stock to 332,172 shares.
On February 17, 2026, Sun received a grant of 4,817 restricted stock units, which each represent a right to one share of Cognex common stock and vest 100% on the first anniversary of the grant date. The filing also lists stock options and common shares held indirectly through Sun Management Associates, LLC, where he disclaims beneficial ownership beyond his pecuniary interest.
Cognex Corporation filed an amended report to update details on its change of independent auditor. The Audit Committee selected KPMG LLP as auditor for the fiscal year ending December 31, 2026, replacing Grant Thornton LLP after Grant Thornton completed its audit of the 2025 financial statements on February 13, 2026.
Grant Thornton’s reports on Cognex’s consolidated financial statements for the years ended December 31, 2025 and 2024 contained no adverse opinions, disclaimers, or qualifications. The company reports no disagreements or reportable events with Grant Thornton and states it did not consult KPMG on specific accounting issues or audit opinions during 2024, 2025, or through February 13, 2026.
Cognex Corp director Robert Willett exercised stock options and sold the resulting shares in a same-day transaction. On 02/13/2026 he exercised 2,148 non-qualified stock options at $39.44 per share, receiving 2,148 shares of common stock, then sold those 2,148 shares at an average price of $59.5011 per share under a Rule 10b5-1 trading plan. Following these transactions he reported no directly held common shares, while continuing to hold multiple option grants and restricted stock units, plus 15,804 common shares held indirectly through the Willett Parkhill Investment Trust, where he is trustee and beneficiary and disclaims beneficial ownership beyond his pecuniary interest.
Cognex Corporation announced that its Board of Directors has appointed Dr. Sami Atiya and Mr. Chris Donato as directors, effective March 2, 2026. Dr. Atiya’s term will run to the 2028 annual meeting, while Mr. Donato’s term will run to the 2026 annual meeting.
Dr. Atiya is expected to join the Nominating, Governance and Sustainability Committee, and Mr. Donato is expected to join the Compensation Committee. Each will receive a $50,000 annual cash retainer, plus $5,000 for Dr. Atiya’s committee role and $8,000 for Mr. Donato’s committee role, along with initial RSU grants valued at about $275,000 that vest after one year.
In connection with these appointments, former CEO Robert Willett and Dr. Dianne Parrotte will retire from the Board on March 2, 2026, continuing an ongoing refresh of Cognex’s board with independent directors who bring automation, AI, and enterprise sales expertise.
Cognex director Robert Willett reported exercising stock options and selling the resulting shares on 02/12/2026. He exercised options for 173,296 shares at $38.39 and 3,756 shares at $39.44, then sold all 177,052 shares of common stock at an average price of $58.3851 per share in open-market transactions.
The filing shows remaining direct holdings of multiple non-qualified stock options covering hundreds of thousands of shares with exercise prices from $33.04 to $90.5, plus 70,824 restricted stock units and 15,804 shares held indirectly by a trust where Willett is trustee and beneficiary. The stock option exercises were carried out under a pre-established Rule 10b5-1 trading plan.